Author

Mingzhao Zhu

Baylor UniversityORCID 0000-0003-2001-2669Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

Agnès BassevilleiD· 1 shared Amy W. KuiD· 1 shared Changjie LouiD· 1 shared Christopher B. DamociiD· 1 shared Daniel RomoiD· 1 shared Diana V. MoralesiD· 1 shared Guangtao Song· 1 shared Hang ZhouiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Agnès BassevilleORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mechanical force regulates the inhibitory function of PD-1

Hui Chen, Yong Zhang, Lei Cui, Juan Fan, Huaying Zhu, Songfang Wu, Hang Zhou, Yanruo Zhang, Guangtao Song, Ning Jenny Jiang, Mingzhao Zhu, Changjie Lou, Wei Chen, Jizhong Lou

This study shows that PD-1 ligand interactions are force-dependent and soluble PD-L1 can block PD-1, suggesting new approaches for cancer immunotherapy.

EMBO Reports · Feb 25, 2026Peer-reviewedBiophysics

Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma

Maryam Safari, Luigi Scotto, Agnès Basseville, Thomas Litman, Haoran Xue, Lubov Petrukhin, Ping Zhou, Helen Elaine Remotti, Amy W. Ku, Diana V. Morales, Christopher B. Damoci, Mingzhao Zhu, Ravikanth Maddipati, Kenneth G. Hull, Robert W. Robey, , Susan Elaine Bates

This paper shows that combining HDAC and eIF4A inhibitors effectively treats pancreatic cancer by inducing epigenetic reprogramming and metabolic stress in preclinical models.

Drug Resistance Updates · Oct 5, 2025Peer-reviewedCancer Biology